Contrasting of ChromaDex Corporation (CDXC) and Adverum Biotechnologies Inc. (NASDAQ:ADVM)

ChromaDex Corporation (NASDAQ:CDXC) and Adverum Biotechnologies Inc. (NASDAQ:ADVM) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ChromaDex Corporation 30.02M 6.67 33.92M -0.63 0.00
Adverum Biotechnologies Inc. 2.00M 114.56 71.76M -1.04 0.00

Demonstrates ChromaDex Corporation and Adverum Biotechnologies Inc. earnings per share, top-line revenue and valuation.


Table 2 provides us ChromaDex Corporation and Adverum Biotechnologies Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
ChromaDex Corporation -112.99% -77.8% -61.9%
Adverum Biotechnologies Inc. -3,588.00% -32.7% -30.8%

Risk & Volatility

ChromaDex Corporation’s current beta is 1.26 and it happens to be 26.00% more volatile than S&P 500. Adverum Biotechnologies Inc.’s 272.00% more volatile than S&P 500 which is a result of the 3.72 beta.


The Current Ratio and a Quick Ratio of ChromaDex Corporation are 3.2 and 2.7. Competitively, Adverum Biotechnologies Inc. has 22.1 and 22.1 for Current and Quick Ratio. Adverum Biotechnologies Inc.’s better ability to pay short and long-term obligations than ChromaDex Corporation.

Insider & Institutional Ownership

Roughly 17.7% of ChromaDex Corporation shares are owned by institutional investors while 70.1% of Adverum Biotechnologies Inc. are owned by institutional investors. About 2.3% of ChromaDex Corporation’s share are owned by insiders. Insiders Comparatively, owned 1.2% of Adverum Biotechnologies Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ChromaDex Corporation -19.72% -22.97% -25.59% -25.39% -54.4% -51.53%
Adverum Biotechnologies Inc. 2.51% -0.27% -45.07% -40.65% 13.23% 5.14%

For the past year ChromaDex Corporation has -51.53% weaker performance while Adverum Biotechnologies Inc. has 5.14% stronger performance.

ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.